Innovation

Advancing the industry’s most comprehensive ophthalmic surgical and pharmaceutical pipeline

At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.

We’ve achieved many firsts in clinical studies, and continue to reinvest 27% of net sales* exclusively on research and development efforts – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.

Man looking using microscope

*2018 Glaukos fiscal year

See Clinical Trials

Glaukos is excited to announce that we have acquired Avedro, Inc.!